Core Labs (CLB) Tops Q1 EPS by 1c; Guides Q2, FY11
Core Laboratories NV (NYSE: CLB) reported Q1 EPS of $0.77, $0.01 better than the analyst estimate of $0.76. Revenue for the quarter came in at $206.73 million versus the consensus estimate of $202.34 million.
Sees Q2 sales of $215 - $220 million, versus $218.7 million. Sees EPS of 84-88c, vs. the consensus of 88c.
Sees FY11 sales of $890-$910 million, which compares to the Street estimate of $894.2 million. Sees EPS of $3.55-$3.60, vs. the consensus of $3.63.
Sees Q2 sales of $215 - $220 million, versus $218.7 million. Sees EPS of 84-88c, vs. the consensus of 88c.
Sees FY11 sales of $890-$910 million, which compares to the Street estimate of $894.2 million. Sees EPS of $3.55-$3.60, vs. the consensus of $3.63.